Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Average Price Target of $29.00 According to Brokerages

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $29.00.

Several brokerages have weighed in on KMTS. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Evercore assumed coverage on Kestra Medical Technologies in a report on Tuesday, October 20th. They set an “outperform” rating and a $34.00 target price on the stock. Royal Bank Of Canada set a $30.00 price target on Kestra Medical Technologies in a research report on Tuesday, September 15th. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th.

Insider Buying and Selling

In related news, Director Conor Hanley sold 5,694 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total transaction of $143,773.50. Following the sale, the director owned 6,272 shares in the company, valued at approximately $158,368. This trade represents a 47.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $29.56, for a total transaction of $443,400.00. Following the completion of the transaction, the insider directly owned 445,215 shares in the company, valued at $13,160,555.40. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 289,551 shares of company stock worth $8,171,898. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sei Investments Co. increased its stake in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after buying an additional 22,471 shares during the last quarter. Corient Private Wealth LP lifted its position in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after buying an additional 44,839 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies in the first quarter valued at about $603,000.

Kestra Medical Technologies Stock Up 0.4%

NASDAQ KMTS opened at $29.81 on Tuesday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. Kestra Medical Technologies has a 1-year low of $17.34 and a 1-year high of $31.06. The company has a 50 day moving average of $26.75 and a 200-day moving average of $23.86.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The company had revenue of $30.97 million for the quarter. As a group, equities research analysts expect that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.